In Denmark 20% of all deaths are caused by cardiac arrest due to coronary thrombosis, a condition caused by coronary artery disease, which a newly founded company aims to help diagnose with a novel heart plaster that is under development. Acarix is the name of the new firm founded by Coloplast and Aalborg University, which respectively have a 37% and 27.5% shareholding, while the remaining shares are owned by Acarix's management and others who have invested in the technology.
Acarix MD Peter Samuelsen says in a press release from Aalborg University: "Blood vessel narrowing around the heart is a disorder which can afflict all of us without warning and with fatal consequences. This is the problem we are now addressing, and although the diagnosis method is still under development we hope to have the technology on the market in three to four years."
The method is based on a plaster applied to the patient's chest which uses advanced listening technology and a computer programme with algorithms that can analyse the sounds for early signs of coronary artery disease.
The technique was invented by two Aalborg University postgraduate students, Samuel Schmidt and Claus Graff, who initially used a digital stethoscope as a listening device. They were awarded the Medico Prize in 2007 for their idea.
Since then the method has been refined and according to professional journal Ingeniøren (The Engineer), Acarix's objective is to be able to take just 3 minutes to diagnose whether a patient is at risk of coronary thrombosis.
The new company is now seeking more investment for its development plans. "Some of the first things we need to look at is to raise fresh capital. We are looking at opportunities on the Danish market, but also on the Scandinavian and international market, and although times are tough there are funds which still have liquid assets," says Peter Samuelsen.